20.01.2021
Issuance of a 5th tranche of 3 millions EUR of notes convertible into new shares
DEINOVE strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal...
Press releases
03.12.2020
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
01.10.2020
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
17.06.2020
Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares
DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020
Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships
• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
30.03.2020
In a climate of economic and industrial uncertainty, the collaboration agreement between Sharon Laboratories and Deinove will not be signed
The current health, economic and financial crisis creates too much uncertainty to enter into a long-term full partnership around a complete...
20.01.2020
DEINOVE announces its financial calendar for 2020
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
26.09.2019
2019 Half-year consolidated results: Deinove’s progress coming to fruition
Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
09.07.2019
Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
28.03.2019
2018 Annual Results: a year of significant progress
Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...